NYSE - Nasdaq Real Time Price USD

ADC Therapeutics SA (ADCT)

Compare
1.2500
-0.0800
(-6.02%)
As of 2:24:57 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
70,837
70,837
69,558
209,908
33,917
Cost of Revenue
5,949
5,949
2,529
3,301
1,393
Gross Profit
64,888
64,888
67,029
206,607
32,524
Operating Expense
194,479
194,479
232,080
329,594
293,878
Operating Income
-129,591
-129,591
-165,051
-122,987
-261,354
Net Non Operating Interest Income Expense
-37,939
-37,939
-35,785
-34,163
-18,274
Other Income Expense
11,394
11,394
5,417
10,333
28,123
Pretax Income
-156,136
-156,136
-195,419
-146,817
-251,505
Tax Provision
166
166
39,106
227
-21,479
Earnings from Equity Interest Net of Tax
-1,544
-1,544
-5,528
-10,084
--
Net Income Common Stockholders
-157,846
-157,846
-240,053
-157,128
-230,026
Diluted NI Available to Com Stockholders
-157,846
-157,846
-240,053
-157,128
-230,026
Basic EPS
-1.62
--
-2.94
-1.99
-3.00
Diluted EPS
-1.62
--
-2.94
-1.99
-3.00
Basic Average Shares
97,159.9660
--
81,712.1660
78,152.9640
76,675.3330
Diluted Average Shares
97,159.9660
--
81,712.1660
78,152.9640
76,675.3330
Total Operating Income as Reported
-130,654
-130,654
-165,986
-123,344
-261,720
Total Expenses
200,428
200,428
234,609
332,895
295,271
Net Income from Continuing & Discontinued Operation
-157,846
-157,846
-240,053
-157,128
-230,026
Normalized Income
-157,772.8000
-157,772.8000
-240,005.4200
-141,963.7050
-261,849.4416
Interest Income
12,272
12,272
10,540
2,568
66
Interest Expense
50,211
50,211
46,325
36,731
18,340
Net Interest Income
-37,939
-37,939
-35,785
-34,163
-18,274
EBIT
-105,925
-105,925
-149,094
-110,086
-233,165
EBITDA
-102,649
-102,649
-145,827
-107,698
-230,535
Reconciled Cost of Revenue
5,949
5,949
2,529
3,301
1,393
Reconciled Depreciation
3,276
3,276
3,267
2,388
2,630
Net Income from Continuing Operation Net Minority Interest
-157,846
-157,846
-240,053
-157,128
-230,026
Total Unusual Items Excluding Goodwill
-80
-80
-52
-16,573
34,795
Total Unusual Items
-80
-80
-52
-16,573
34,795
Normalized EBITDA
-102,569
-102,569
-145,775
-91,125
-265,330
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-6.8000
-6.8000
-4.4200
-1,408.7050
2,971.5584
12/31/2021 - 5/18/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PDSB PDS Biotechnology Corporation
1.0500
-9.01%
 
ABOS Acumen Pharmaceuticals, Inc.
0.9901
-8.32%
 
STRO Sutro Biopharma, Inc.
0.5736
-9.01%
 
SNDX Syndax Pharmaceuticals, Inc.
12.49
-3.70%
 
IPHA Innate Pharma S.A.
1.9300
+7.82%
 
MGNX MacroGenics, Inc.
1.1300
-7.38%
 
QTTB Q32 Bio Inc.
1.6300
+9.76%
 
MRSN Mersana Therapeutics, Inc.
0.3260
-4.09%
 
KURA Kura Oncology, Inc.
6.16
-5.60%
 
BCYC Bicycle Therapeutics plc
7.46
-7.36%